Biphenotypic acute leukemia (BAL) is a rare type of leukemia, and its unique clinical and biological characteristics and prognosis. BAL in the diagnosis and treatment are different from a single type of leukemia. Therefore, we retrospectively analyzed six cases of BAL patients, these patients are in accordance with the European Cooperative Group International Leukemia (EGIL) 1995 standard and the diagnosis of biphenotypic acute leukemia. In this study, we have six cases of BAL specimens of bone marrow cells by light microscopy, respectively, morphological and cytochemical staining to determine their FAB type; the application of flow cytometry immunophenotyping to do, namely, the use of a series of single - Detection of cell membrane antibodies and antigen expression in the cytoplasm; At the same time, the use of G-banding karyotype analysis techniques; the use of both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) treatment in the treatment of four cases in this group of patients with BAL. At present, we have found about the same period of BAL in patients with the diagnosis of acute leukemia of 9.6%. BAL in patients with clinical manifestations in patients with AML and ALL was no significant difference; morphology on the performance of BAL for the AML-M2, M5 and ALL-L3; Immunophenotyping showed that BAL patients with myeloid, B Department of expression were found . In addition, HLA-DR, CD34 positive in the high expression in BAL, suggesting that BAL may be the origin of the leukemic cells in the early hematopoietic cells; karyotype analysis of chromosome abnormalities can be seen, but the study subjects can not be confirmed whether the abnormal karyotype with specificity. BAL in patients with poor response to treatment, the disease risks of poor prognosis. Four cases of treatment of patients with BAL for the first time of chemotherapy complete remission one cases, accounting for 25%. Another in the second two cases of complete remission after chemotherapy, the remaining case of 3,4 for the first course of treatment has yet to ease.
Biphenotypic acute leukemia (BAL) is a rare type of leukemia, and its unique clinical and biological characteristics and prognosis. BAL in the diagnosis and treatment of different types of leukemia a single. Therefore, we retrospectively analyzed six cases of BAL patients, these patients are in accordance with the European Cooperative Group International Leukemia (EGIL) 1995 standard and the diagnosis of biphenotypic acute leukemia.
In addition, HLA-DR, CD34 was high in the BAL in the expression of the leukemia cells Tip BAL probably originated in the early hematopoietic cells; karyotype analysis of chromosome abnormalities can be seen, but the study subjects can not be confirmed whether the abnormal karyotype with specificity. BAL in patients with poor response to treatment, the disease risks of bad prognosis. Four cases of treatment of patients with BAL for the first time chemotherapy complete remission of Example 1, accounting for 25%. Another in the second two cases of complete remission after chemotherapy, the remaining case of 3,4 for the first course of treatment has yet to ease.
内容全部来源于网络收集，如有侵权，请联系网站删除：QQ：24596024